Form 4: Centene CEO Sarah London Reports Stock Transaction
SEC Form 4 Filing
Centene CEO Sarah London reports the withholding of shares for taxes upon vesting of restricted stock units.
Summary
- On September 7, 2024, Centene CEO Sarah London reported a transaction involving common stock.
- 48,565 shares were withheld for taxes upon the vesting of previously-reported restricted stock units at a price of $70.83.
- Following the transaction, London directly owns 663,112 shares of Centene stock.
- This ownership includes 488,652 shares of previously-granted restricted stock units and performance stock units (reported at target level performance) subject to vesting requirements.
- London also holds options to purchase 13,449 shares of common stock at an exercise price of $81.85, which may become exercisable on or after December 15, 2024, if Centene's stock price reaches $100 for 20 consecutive trading days.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a routine stock transaction. It doesn't inherently convey positive or negative sentiment about the company's performance or prospects.
Future Outlook
The document does not contain explicit forward-looking statements regarding Centene's future performance, but it does mention conditions under which stock options may become exercisable, which depends on the company's stock price performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the CEO's stock ownership and recent activity, which investors may consider when evaluating the company's leadership alignment with shareholder interests.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- The vesting schedules and performance-based conditions for these equity grants are typical in the healthcare industry and among S&P 500 companies.
- Comparing Sarah London's stock ownership and option grants to those of CEOs at similar companies like UnitedHealth Group (UNH) or CVS Health (CVS) could provide a benchmark for assessing the size and structure of her compensation package.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects the CEO's stock ownership and alignment with company performance.
- Employees may be interested in the vesting schedules and performance conditions of executive equity grants.
Key Dates
| Date | Description |
|---|---|
| 12/15/2021 | Date of Performance Stock Option grant. |
| 09/07/2024 | Date of stock transaction (shares withheld for taxes). |
| 09/09/2024 | Date of signature on the Form 4 filing. |
| 12/15/2024 | Earliest date the Performance Stock Option may become exercisable. |
| 12/15/2031 | Expiration date of the Common Stock Option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.